Cancer
Study Shows Mammography Reminders Work
Increasing the number of women who get annual mammograms could simply be a matter of putting better reminder systems in place, a new study shows. More »
Study Findings Provide New Insights Into Lymphoma Therapy
Researchers detail in 'Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma,' new data in lymphoma. "Most patients with Hodgkin lymphoma (HL) are cured with first and second-line treatment; however, the outcome is unknown for those who fail high dose chemoradiotherapy with autologous stem cell transplant (HDT-ASCT). This report is an analysis of patients with relapsed and primary refractory HL who were treated with HDT-ASCT and failed due to progression of disease (POD)," scientists in the United States report. "Two hundred and two patients received HDT-ASCT at Memorial Sloan-Kettering Cancer Center for relapsed or refractory HL between December 19... More »
Acceleron And Celgene Initiate Phase 2 Study Of ACE-011 To Treat Chemotherapy-Induced Anemia
CAMBRIDGE, Mass. -- Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone and muscle, and Celgene Corporation today announced the initiation of a second Phase 2 clinical study of ACE-011. This Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study designed to evaluate the potential of ACE-011 to treat chemotherapy-induced anemia in patients with metastatic breast cancer. ACE-011 is a novel therapeutic agent that has been shown to increase levels of red blood cells and hemoglobin and stimulate new bone formation. ACE-011 works through a novel mechanism by inhibiting certain members of the TGF-b... More »
CytRx Drug Candidate INNO-206 Results In Ovarian Tumor Shrinkage in Animal Trials
LOS ANGELES -- CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that results demonstrating that its cancer drug candidate INNO-206 caused statistically significant tumor shrinkage in an animal model of ovarian cancer have been accepted for publication in the peer-reviewed journal Investigational New Drugs. The manuscript based on this animal trial, "INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model," was made available ahead of journal printing in electronic format... More »
Ovarian Cancer Tests Flawed, In Need Of New Design, Says Stanford Study
STANFORD, Calif. -- Current diagnostic tests for ovarian cancer are woefully ineffective for early detection of the disease, say researchers at Stanford University School of Medicine. A new study finds that in order to make a significant dent in the mortality rate for the deadly cancer, the tests would have to be able to detect tumors of less than 1 cm in diameter, or about 200-times smaller in mass than those currently used to assess potential new tests. Still, if that hurdle can be overcome, there is good reason to believe that testing could make a big difference: The window of opportunity for treating these clinically undetectable cancers before they become life threatening is surprisingly long: about four years. "We... More »
ASTRO Issues Consensus Statement On Using APBI To Treat Breast Cancer
The American Society for Radiation Oncology has published a consensus statement outlining patient selection criteria and best practices for the use of accelerated partial breast irradiation (APBI) outside the context of a clinical trial in the July 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO. For decades, whole-breast irradiation (WBI), where radiation is delivered to the whole breast every day for five to eight weeks, has been the standard treatment for patients with early breast cancer treated with breast conserving surgery. WBI has been shown to reduce the risk of recurrence in the affected breast and increase the likelihood of long-term survival. However, recently there h... More »
Racial Disparity Of Breast Cancer Deaths Baffles Researchers: The Roles Of Genetics And Environment Are Being Investigated
A new study that suggests that racial differences in biology could be a key reason black women are more likely to die of breast cancer than white women has reignited an intense debate among medical experts about the role of genetics versus factors such as poverty, diet and unequal access to quality health care. For nearly three decades, researchers have known about the disparity in death rates, but they have been puzzled over the reasons why. In Maryland, for example, the breast cancer death rate for black women is 15 percent higher than for white women, even though African-Americans have a lower incidence of the disease. State health officials, doctors and advocacy groups have long thought a combination of factors explained the disparit... More »
Higher Insulin Levels May Increases Risk For Breast Cancer
LOS ANGELES -- Postmenopausal women with elevated insulin levels may face greater risk of developing breast cancer, a new study has found. U.S. researchers drew the conclusion after examining data on 5, 450 women who took part in the Women's Health Initiative, a large study that looked at how various factors influence women's health, according to the study published online on Thursday in the International Journal of Cancer. The study was conducted by researchers at Albert Einstein College of Medicine of Yeshiva University in New York City. The researchers found a strong association between elevated insulin levels in the blood and increased risk of breast cancer. Women with insulin levels in the highest third were t... More »
Oncovista Innovative Therapies, Inc. Announces The Initiation Of Clinical Development Of Adnagen's Breast Cancer Circulating Tumor Cells Diagnostic Technology In Women With High-Risk Locally Advanced Breast Cancer
SAN ANTONIO -- OncoVista Innovative Therapies, Inc. and AdnaGen Ag announced that The University of Texas M. D. Anderson Cancer Center will collaborate on clinical studies of AdnaGen's molecular based CTC technology in Women with High-Risk Locally Advanced Breast Cancer (LABC) that have completed Neoadjuvant and Local Therapy. "M. D. Anderson is dedicated to helping develop novel approaches that may improve the prognosis of patients with malignant diseases," said Dr. Massimo Cristofanilli, Associate Professor of Medicine and the Director of the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic. Dr. Cristofanilli added: "We are dedicated to improving the prognosis of patients with advanced breast canc... More »
Research From National Cancer Institute In The Area Of Breast Cancer Described
"Physical activity is being studied as a breast cancer prevention strategy. Women at risk of breast cancer report interest in lifestyle modification, but recruitment to randomized physical activity intervention studies is challenging," scientists in the United States report. "We conducted an analysis of recruitment techniques used for a prospective, randomized pilot study of physical activity in women at risk of breast cancer. We evaluated differences in proportion of eligible patients, enrolled patients, and successful patients identified by each individual recruitment method. The Fisher-Freeman-Halton test (an extension of Fisher's exact test from 2 x 2 tables to general row by column tables) was used to compare the success of different... More »